Results 121 to 130 of about 93,200 (346)

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis within a Longitudinal Cohort

Arthritis &Rheumatology, Accepted Article.
Objective To estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axSpA and to identify factors associated with D2M/TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis Program cohort.
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Mortality trends in a Cohort of Canadian Psoriatic Arthritis Patients

McGill Journal of Medicine, 2020
Methods: We reviewed retrospectively the charts of psoriatic arthritis patients who died from 1995-2010.We included 13 deceased patients with a psoriatic arthritis di-agnosis and compared them with 140 patients living with psoriatic arthritis that at ...
Boluwaji Ogunyemi
doaj  

REVISITING THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS

Alʹmanah Kliničeskoj Mediciny, 2016
Aim: To study clinical and x-ray characteristics of psoriatic arthritis in patients with psoriasis during hospital treatment in the Dermatovenereology and Dermato-Oncology Department of the Moscow Regional Research and Clinical Institute (MONIKI ...
E. S. Yakubovskaya
doaj   +1 more source

One year in review: ultrasound in arthritis [PDF]

, 2016
Musculoskeletal ultrasound (MSUS) has become a relevant part of rheumatology practice and research because it substantially allows us to optimize management of rheumatic and musculoskeletal diseases. This non-invasive imaging modality is a valuable point-
IAGNOCCO, Annamaria, Naredo, Esperanza
core  

Myelodysplasia in a psoriasis patient receiving etanercept : Cause or coincidence? [PDF]

, 2018
Peer reviewedFinal Accepted ...
Ayoub, Othman Hadi, Dawoud, Dalia M, Dawoud, Noha Mohammed, Essa, Enas Said   +3 more
core   +3 more sources

217. Long-Term 52-Week Results of Palace 1, A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase Inhibitor, In atients with Psoriatic Arthritis [PDF]

, 2014
Adewale Adebajo, Arthur Kavanaugh, Philip J. Mease, J. Wollenhaupt, ChiaChi Hu, K. Shah, Randall M. Stevens, Juan J. Gómez‐Reino   +7 more
openalex   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

SAT0394 POSSIBLE POTENTIAL INTERACTIONS BETWEEN OBESITY, QUALITY OF LIFE, PSYCHOLOGICAL STATUS AND CLINICAL PARAMETERS IN PSORIATIC ARTHRITIS [PDF]

, 2019
Kevser Gök, Kemal Nas, Erkan Kılıç, Betül Sargın, Sevtap Acer Kasman, Hakan Alkan, Nilay Şahin, Gizem Cengiz, Nihan Cüzdan, İlknur Albayrak Gezer, Dilek Keskin, Cevriye Mülkoğlu, Hatice Resorku, İsmihan Sunar, Ajda Bal Hastürk, Mehmet Tuncay Duruöz, Okan Küçükakkaş, Ozan Volkan Yurdakul, Meltem Alkan Melikoğlu, Yıldıray Aydın, Fikriye Figen Ayhan, Hatice Bodur, Mustafa Çalış, Erhan Çapkın, Gül Devrimsel, Sami Hizmetli, Ayhan Kamanlı, Yaşar Keskin, Hilal Kocabaş, Öznur Kutluk, Nesrin Şen, Ömer Faruk Şendur, İbrahim Tekeoğlu, Murat Toprak, Sena Tolu, Tiraje Tuncer   +35 more
openalex   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source